Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes

Not Applicable

Completed

• Conditions: Type 2 diabetes; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN35210312
• Lead Sponsor: Okhotsk-kai Hospital (Japan)

Brief Summary

2008 Results article in https://pubmed.ncbi.nlm.nih.gov/19149832/ (added 29/10/2021)

Detailed Description

Not available

Study Timeline

• Study Completion: 2006-12-31
• Study Start: 2007-08-17
• Last Update Posted: 8 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

1. Patients with type 2 diabetes under long-term insulin injection
2. Age between 40 and 86 years
3. Insulin dosage >10 units/24 h
4. Insulin injection duration >3 months
5. C-peptide in 24-hr urine >10 micrograms
6. Fasting CPR >0.5 ng/ml

Exclusion Criteria

1. Positive for glutamine acid decarboxylase antibody
2. ALT and/or AST >3 times the upper limit of normal
3. Presently and/or in the past suffering from heart failure
4. Ejection fraction assessed by echocardiography <40%
5. Malignancy on active therapeutic regimen or without complete remission or cure
6. Concomitantly suffering from infection
7. Planning to have surgery
8. >50% positivity for insulin antibody
9. Diagnosis of type I diabetes
10. Pregnant or breast feeding
11. Under dialysis
12. Concomitantly using pioglitazone

Study & Design

• Study Type: Interventional
• Study Design: Not specified